BioHorizon Health Technology Surveillance Update: February 8, 2010

The BioHorizon Health Technology Surveillance Update gives readers a concise,  high level overview of the most important emerging health technology developments on a ongoing basis  including key FDA approvals, substantive clinical trial results and upcoming events of importance. First of all, on behalf of  the entire BioHorizon staff, let me welcome you to the BioHorizon Health [...]

Oral Therapies for Multiple Sclerosis – Fingolimod (FTY 720) and Cladribine: How Close are Novartis and Merck KGaA to FDA Approval?

These are interesting days for the first oral therapies targeting multiple sclerosis (cladribine and  fingolimod or FTY720) indeed, with both positive and negative events making news over the last several weeks.  On November 30th 2009,  Reuters reported that the FDA had issued Merck KGaA a ‘refuse to file’ letter, which in effect is the FDA’s way [...]